| Patent Number |
Title Of Patent |
Date Issued |
| 7390626 |
Methods and kit for diagnosing tick borne illnesses |
June 24, 2008 |
| ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, |
| 7258994 |
Saliva immunoassay for detection of antibodies for cardiovascular disease |
August 21, 2007 |
| A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, .beta.-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immun |
| 7252957 |
Identification of etiology of autism |
August 7, 2007 |
| Disclosed herein is a method for following up a prognosis of children with autism before and after treatment with different modalities administered by their clinicians, confirming the involvement of infectious agents, dietary proteins, and toxic chemicals in development of autism. The |
| 6858398 |
Saliva test for detection of food allergy and intolerance |
February 22, 2005 |
| A method for determining the presence of food allergy or food intolerance and their cross-reactive tissue antigens is disclosed. The method includes determining a level of antibodies against a dietary antigen in a mucosal sample from the patient and comparing the level with normal levels |
| 6815161 |
Detection of Mycoplasma in patients with chronic fatigue syndrome and related disorders |
November 9, 2004 |
| A method for determining an increased likelihood of the presence of chronic fatigue syndrome (CFS), fibromyalgia (FMS), or rheumatoid arthritis (RA) in an individual, comprising isolating blood cells from the individual and determining the presence of one or more Mycoplasma species prese |
| 6689569 |
Saliva test for detection of food allergy, candidiasis, microflora imbalance, intestinal barrier |
February 10, 2004 |
| A method for determining a cause for digestive and immune disorders is disclosed. The method determines the levels of antibodies against normal intestinal microflora and food antigens. It then compares the results to normal levels to determine the cause. The test can be used to diagnose |
| 6103480 |
Single blood test for detection of food allergy, candidiasis, microflora imbalance, intestinal b |
August 15, 2000 |
| A method for determining a cause for digestive and immune disorders is disclosed. The method determines the levels of antibodies against normal intestinal microflora and food antigens. It then compares the results to normal levels to determine the cause. The test can be used to diagnose |
| 6020205 |
Determination of intracellular antioxidant levels |
February 1, 2000 |
| A method of determining intracellular levels of water-soluble and fat-soluble antioxidants. Peripheral blood mononuclear cell lysates are prepared from an individual and analyzed by HPLC, either directly or after extraction with organic solvents to extract fat-soluble antioxidants. The |
| 5853996 |
Detection of chronic fatigue syndrome by increased apoptosis and cell cycle arrest of peripheral |
December 29, 1998 |
| A method for diagnosing chronic fatigue syndrome in an individual. Peripheral blood monocytes are isolated and p68 kinase activity, mRNA levels, protein levels, apoptosis and cell cycle analysis are measured. Significantly increased levels of any of these compared to healthy control |
| 5830668 |
Detection of chronic fatigue syndrome |
November 3, 1998 |
| A method for diagnosing chronic fatigue syndrome in an individual. Peripheral blood monocytes are isolated and p68 kinase activity, mRNA levels, protein levels, apoptosis and cell cycle analysis are measured. Significantly increased levels of any of these compared to healthy control |
| 5766859 |
Ribonuclease L inhibitor as an indicator of chronic fatigue syndrome |
June 16, 1998 |
| Chronic fatigue syndrome in an individual is diagnosed by determining the level of RNase L inhibitor mRNA or protein in peripheral blood mononuclear cells. Significantly decreased levels of RLI mRNA or protein compared to healthy control individuals indicates the presence of chronic fati |
